What are the side effects of Ponatinib?

The most common adverse reactions identified in the Heads of Prescribing Information were from a pooled safety population of 543 patients with chronic myelogenous leukemia (CML) or Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ALL) who received Ponatinib at a starting dose of 45 mg orally once daily. The most common Grade 3 or 4 laboratory abnormalities (>20%) were decreased platelet count, decreased neutrophil count, and leukopenia.

The most common adverse reactions(>20%) in this summary safety population were rash and related symptoms, arthralgia, abdominal pain, headache, constipation, dry skin, hypertension, fatigue, fluid retention and edema, pyrexia, nausea, pancreatitis/lipase elevation, bleeding, anemia, liver function abnormalities, and AOE. Post-marketing adverse reactions of ponatinib include thrombotic microangiopathy, hyperthyroidism, gastrointestinal perforation (fistula), dehydration, reversible posterior leukoencephalopathy syndrome (RPLS), severe skin reactions (such as erythema multiforme, Stevens-Johnson syndrome), impaired wound healing, arterial (including aorta) aneurysms, dissections and ruptures.

The original drug of Ponatinib has not yet been launched in China, so it is not included in the medical insurance. Domestic patients in need may only purchase it through overseas channels. The Hong Kong original version of Ponatinib specificationsThe price of 45mg*30 tablets per box may be around 40,000 yuan (the price may fluctuate due to the exchange rate), which is expensive. There are also generic ponatinib drugs produced in other countries, which are relatively cheap. The price of 45mg*30 tablets per box produced by Everest Pharmaceutical Factory in Bangladesh may be around 4,000 yuan (the price may fluctuate due to the exchange rate), and its drug ingredients are basically the same as those of the original drug.